Trevi Therapeutics, Inc.

TRVI

NASDAQHealthcareBiotechnology

在 GoAI 中打开

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

48/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Expensive

动量

Gaining

情绪

Mixed

风险韧性

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Jennifer L. Good
上市以来: 2019年5月7日
雇员: 34